| Literature DB >> 31922357 |
Fangyu Chen1,2, Li Chu3,4, Jie Li1, Yu Shi5, Bing Xu1,2, Junjie Gu1,2, Xijuan Yao1,2, Meng Tian1, Xi Yang3,4, Xinchen Sun2.
Abstract
BACKGROUND: Extracellular vesicles (EVs) are endogenous membrane vesicles with a diameter of 30-200 nm. It has been reported that hypoxic cancer cells can release numerous EVs to mediate multiple regional and systemic effects in the tumor microenvironment.Entities:
Keywords: Esophageal cancer; extracellular vesicles; hypoxia; microRNA; tumor microenvironment
Mesh:
Substances:
Year: 2020 PMID: 31922357 PMCID: PMC7049507 DOI: 10.1111/1759-7714.13295
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Figure 1Confirmation of hypoxia and identification of EVs from TE‐13 cells. (a) Hypoxia environment was confirmed by HIF‐1α expression; (b) EVs were defined by a lipid bilayer under TEM; (c) NTA analysis showing the mean vesicle size distribution of 74.1 nm; (d) Western blot of EVs showing enriched expression of exosomal marker CD63 and CD81 and no expression of endoplasmic reticulum protein Calnexin.
Figure 2Differentially expressed miRNAs in hypoxic and normoxic EVs. (a) Heat map showing clustering of changed miRNAs. Red represents upregulated miRNAs and blue represents downregulated miRNAs; (b) Venn diagram showing the number of overlapped miRNAs in each group; (c) Volcano plot revealing altered miRNAs in hypoxic and normoxic EVs; (d) Bar plot indicating number of altered miRNAs after hypoxia treatment at different P‐values. up, no_diff, down, up‐regulated, down‐regulated.
Significantly altered miRNAs in hypoxic EVs (P < 0.01) *inf: infinity
| miRNA | Regulation | Fold change |
|
|---|---|---|---|
| hsa‐miR‐1262 | up | inf* | 0.000869564 |
| hsa‐miR‐769‐5p | up | 3.06 | 0.002934105 |
| hsa‐mir‐1304‐p5 | up | 3.71 | 0.00333358 |
| PC‐3p‐73334_38 | down | 0.23 | 0.003489675 |
| hsa‐miR‐128‐3p | up | 2.02 | 0.003914834 |
| PC‐3p‐2356_1595 | down | 0.17 | 0.004213607 |
| hsa‐miR‐369‐3p | down | 0.39 | 0.005009377 |
| mmu‐let‐7j | up | 4.47 | 0.005458252 |
| hsa‐miR‐95‐3p | up | 2.15 | 0.0062081 |
| hsa‐miR‐532‐5p | up | 2.11 | 0.006414664 |
| hsa‐miR‐140‐3p | up | 2.21 | 0.006570997 |
| PC‐3p‐200028_13 | down | 0.12 | 0.006795539 |
| hsa‐miR‐192‐5p | up | 2.15 | 0.006911668 |
| hsa‐miR‐3143 | up | inf | 0.006983654 |
| hsa‐miR‐340‐5p | up | 2.01 | 0.007744756 |
| PC‐5p‐151105_17 | down | ‐inf | 0.008038862 |
| hsa‐miR‐409‐3p | down | 0.39 | 0.008233985 |
| hsa‐miR‐452‐5p | up | 2.31 | 0.008441793 |
| hsa‐miR‐144‐3p | down | 0.28 | 0.009919166 |
| hsa‐miR‐125b‐1‐3p | up | 9.15 | 0.00968456 |
Figure 3GO and KEGG analysis of differentially expressed miRNAs and target mRNAs. (a) Bar plot revealing GO analysis of molecular function, biological process and cellular component; (b) Scatter plot of GO enrichment analysis; (c) Scatter plot of KEGG signaling pathway analysis. Rich factor = the percentage of enriched genes in the total number of the genes in the pathway.
KEGG pathways affected by altered exosomal miRNAs (P < 0.001)
| KEGG pathway | gene number |
|
|---|---|---|
| Pathways in cancer | 492 | 1.03E‐07 |
| Phospholipase D signaling pathway | 141 | 4.88E‐06 |
| AGE‐RAGE signaling pathway in diabetic complications | 98 | 5.90E‐06 |
| Autophagy ‐ animal | 125 | 7.36E‐06 |
| Focal adhesion | 190 | 1.16E‐05 |
| Platelet activation | 119 | 1.59E‐05 |
| FoxO signaling pathway | 127 | 2.76E‐05 |
| Axon guidance | 167 | 4.51E‐05 |
| Human papillomavirus infection | 297 | 5.05E‐05 |
| mTOR signaling pathway | 144 | 5.47E‐05 |
| Proteoglycans in cancer | 193 | 6.86E‐05 |
| Synaptic vesicle cycle | 63 | 7.90E‐05 |
| Endocytosis | 229 | 8.10E‐05 |
| MAPK signaling pathway | 272 | 9.50E‐05 |
| Hippo signaling pathway | 147 | 1.27E‐04 |
| Rap1 signaling pathway | 194 | 1.57E‐04 |
| Fc gamma R‐mediated phagocytosis | 88 | 1.64E‐04 |
| Thyroid hormone signaling pathway | 112 | 1.68E‐04 |
| Signaling pathways regulating pluripotency of stem cells | 133 | 1.86E‐04 |
| Inositol phosphate metabolism | 73 | 1.96E‐04 |
| Glutamatergic synapse | 110 | 2.13E‐04 |
| PI3K‐Akt signaling pathway | 320 | 2.36E‐04 |
| Phagosome | 141 | 2.41E‐04 |
| HIF‐1 signaling pathway | 97 | 2.52E‐04 |
| Calcium signaling pathway | 170 | 2.55E‐04 |
| Platinum drug resistance | 71 | 2.59E‐04 |
| Breast cancer | 140 | 2.68E‐04 |
| AMPK signaling pathway | 115 | 4.23E‐04 |
| Epithelial cell signaling in Helicobacter pylori infection | 67 | 4.48E‐04 |
| Insulin resistance | 103 | 4.82E‐04 |
| HTLV‐I infection | 235 | 4.86E‐04 |
| Ras signaling pathway | 217 | 5.13E‐04 |
| Chemokine signaling pathway | 172 | 5.18E‐04 |
| Th17 cell differentiation | 101 | 6.07E‐04 |
| Osteoclast differentiation | 120 | 7.57E‐04 |
| Th1 and Th2 cell differentiation | 87 | 8.47E‐04 |
| Lysosome | 118 | 9.35E‐04 |
| Bacterial invasion of epithelial cells | 74 | 9.89E‐04 |
Figure 4Analysis of miRNA‐mRNA regulatory network concerning Phospholipase D signaling pathway. Phospholipase D signaling pathway, gene, miRNA.
Figure 5Verification of differentially expressed miRNA by RT‐PCR in (a) Te13 cells, (b) Te1cells and (c) ECA109 cells. Normoxia, Hypoxia.